311 related articles for article (PubMed ID: 28486684)
1. Superior vasodilation of human pulmonary vessels by vardenafil compared with tadalafil and sildenafil: additive effects of bosentan.
Ried M; Neu R; Lehle K; Großer C; Szöke T; Lang G; Hofmann HS; Hoenicka M
Interact Cardiovasc Thorac Surg; 2017 Aug; 25(2):254-259. PubMed ID: 28486684
[TBL] [Abstract][Full Text] [Related]
2. Combination of sildenafil and bosentan for pulmonary hypertension in a human ex vivo model.
Ried M; Potzger T; Neu R; Sziklavari Z; Szöke T; Liebold A; Hofmann HS; Hoenicka M
Cardiovasc Drugs Ther; 2014 Feb; 28(1):45-51. PubMed ID: 24193244
[TBL] [Abstract][Full Text] [Related]
3. Combination Therapy of Pulmonary Arterial Hypertension with Vardenafil and Macitentan Assessed in a Human Ex Vivo Model.
Hoenicka M; Golovchenko S; Englert L; Spaeth M; Shoshiashvili L; Großer C; Hofmann HS; Ried M
Cardiovasc Drugs Ther; 2019 Jun; 33(3):287-295. PubMed ID: 30826900
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model.
Englert L; Stadlbauer C; Spaeth M; Hofmann HS; Schneider C; Hatz RA; Preissler G; Michel S; Golovchenko S; Ried M; Hoenicka M
Pulm Pharmacol Ther; 2021 Feb; 66():101985. PubMed ID: 33359621
[TBL] [Abstract][Full Text] [Related]
5. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
[TBL] [Abstract][Full Text] [Related]
6. Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets.
Toque HA; Teixeira CE; Priviero FB; Morganti RP; Antunes E; De Nucci G
Br J Pharmacol; 2008 Jun; 154(4):787-96. PubMed ID: 18536732
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
Tsai BM; Turrentine MW; Sheridan BC; Wang M; Fiore AC; Brown JW; Meldrum DR
Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
[TBL] [Abstract][Full Text] [Related]
8. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
Grünig E; Ohnesorge J; Benjamin N; Burhenne J; Enderle Y; Egenlauf B; Fischer C; Harutyunova S; Huppertz A; Klose H; Haefeli WE
Respiration; 2017; 94(1):26-37. PubMed ID: 28494463
[TBL] [Abstract][Full Text] [Related]
9. Acute effect of sildenafil is maintained in pulmonary arterial hypertension patients chronically treated with bosentan.
Hatano M; Yao A; Kinugawa K; Hirata Y; Nagai R
Int Heart J; 2011; 52(4):233-9. PubMed ID: 21828950
[TBL] [Abstract][Full Text] [Related]
10. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC
Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324
[TBL] [Abstract][Full Text] [Related]
11. Choice of Initial Oral Therapy for Pulmonary Arterial Hypertension: Age and Long-Term Survival.
Heresi GA; Love TE; Tonelli AR; Highland KB; Dweik RA
Am J Respir Crit Care Med; 2018 Oct; 198(8):1090-1093. PubMed ID: 29949380
[No Abstract] [Full Text] [Related]
12. [Pharmacological treatment of pulmonary hypertension at a turning point].
Watanabe H
Nihon Yakurigaku Zasshi; 2014 Apr; 143(4):165-72. PubMed ID: 24717603
[No Abstract] [Full Text] [Related]
13. Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan.
Faruqi S; Fathi H; Morice AH
Int J Cardiol; 2010 Oct; 144(3):e43-5. PubMed ID: 19171388
[TBL] [Abstract][Full Text] [Related]
14. Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries.
Liang F; Yang S; Yao L; Belardinelli L; Shryock J
Hypertension; 2012 Mar; 59(3):705-11. PubMed ID: 22311911
[TBL] [Abstract][Full Text] [Related]
15. Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells.
Weiss J; Theile D; Spalwisz A; Burhenne J; Riedel KD; Haefeli WE
Biochem Pharmacol; 2013 Jan; 85(2):265-73. PubMed ID: 23219525
[TBL] [Abstract][Full Text] [Related]
16. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
[TBL] [Abstract][Full Text] [Related]
17. Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension.
Mouchaers KT; Schalij I; Versteilen AM; Hadi AM; van Nieuw Amerongen GP; van Hinsbergh VW; Postmus PE; van der Laarse WJ; Vonk-Noordegraaf A
Am J Physiol Heart Circ Physiol; 2009 Jul; 297(1):H200-7. PubMed ID: 19395550
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
Kim E; Seftel A; Goldfischer E; Baygani S; Burns P
Curr Med Res Opin; 2015 Feb; 31(2):379-89. PubMed ID: 25455432
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
20. Erectile Dysfunction Drugs Changed the Protein Expressions and Activities of Drug-Metabolising Enzymes in the Liver of Male Rats.
Sheweita SA; Wally M; Hassan M
Oxid Med Cell Longev; 2016; 2016():4970906. PubMed ID: 27800121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
